

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4524117

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	MATTHEW J. BUDERER	07/12/2017
	DENNIS SAADEH	07/03/2017
	ANDREW R. BOLL	06/29/2017
RECEIVING PARTY DATA		
Name:	IMPRIMIS PHARMACEUTICALS, INC.	
Street Address:	12626 HIGH BLUFF DRIVE	
Internal Address:	SUITE 105	
City:	SAN DIEGO	
State/Country:	CALIFORNIA	
Postal Code:	92130	
PROPERTY NUMBERS Total: 1		
Property Type	Number	
Application Number:	15620430	
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Email:	ajoseph@lathropgage.com, bostonpatent@lathropgage.com	
Correspondent Name:	LATHROP & GAGE LLP	
Address Line 1:	28 STATE STREET	
Address Line 2:	SUITE 700	
Address Line 4:	BOSTON, MASSACHUSETTS 02109	
ATTORNEY DOCKET NUMBER:	591897: IPI-002CIP	
NAME OF SUBMITTER:	SEAN M. COUGHLIN	
SIGNATURE:	/Sean M. Coughlin/	
DATE SIGNED:	07/27/2017	
Total Attachments: 5		
source=591897_Assignment_from_inventors_to_Imprimis#page1.tif		
source=591897_Assignment_from_inventors_to_Imprimis#page2.tif		
source=591897_Assignment_from_inventors_to_Imprimis#page3.tif		

source=591897_Assignment_from_inventors_to_Imprimis#page4.tif

source=591897_Assignment_from_inventors_to_Imprimis#page5.tif

ASSIGNMENT

WHEREAS, we, **Matthew J. Buderer**, of 230 S. Gordon Drive, Oak Harbor, Ohio 43449, U.S.A., **Dennis Saadeh**, of 12626 High Bluff Drive, Suite 105, San Diego, California 92130, U.S.A., and **Andrew R. Boll**, of 12626 High Bluff Drive, Suite 105, San Diego, California 92130, U.S.A., have invented a certain new and useful invention entitled:

**PHARMACEUTICAL FORMULATIONS OF XANTHINE OR XANTHINE
DERIVATIVES, AND THEIR USE**

U.S. Serial No.: 15/620,430, filed June 12, 2017

for which we have made application for Letters Patent of the United States; and

WHEREAS, **Imprimis Pharmaceuticals, Inc.**, a corporation duly organized under the laws of the United States of America, and having its principal place of business at 12626 High Bluff Drive, Suite 105, San Diego, California 92130, U.S.A., is desirous of acquiring all rights, title and interests in and to said invention, said application(s), and in and to any and all Letters Patent which may be granted for or upon said invention and application(s) in the United States of America and anywhere in the world.

NOW THEREFORE, to all whom it may concern, be it known that for good and valuable consideration, the receipt of which is hereby acknowledged, WE, **Matthew J. Buderer, Dennis Saadeh, and Andrew R. Boll** have sold, assigned and transferred, and by these presents do sell, assign and transfer, unto said **Imprimis Pharmaceuticals, Inc.**, the full and exclusive right, title and interest, throughout the world, in, to and under the following:

(a) said invention as fully set forth and described in the specification prepared, and executed by us preparatory to obtaining Letters Patent of the United States therefor;

(b) said application(s);

(c) any and all refilings, divisions, continuations and continuations-in-part of said application(s);

(d) any and all Letters Patent of the United States of America which may issue from said application(s), refilings, divisions, continuations and continuations-in-part;

(e) any and all reissues and reexaminations of said Letters Patent of the United States of America;

(f) any and all application(s) for Letters Patent upon said invention which may hereafter be filed in any and all countries foreign to the United States of America;

(g) any and all refilings, divisions and continuations of said foreign-filed application(s);


(h) any and all Letters Patent of countries foreign to the United States of America which may issue from the said foreign-filed application(s), refilings, divisions and continuations; and

(i) any and all extensions of, and additions to, said Letters Patent of countries foreign to the United States of America.

WE, **Matthew J. Buderer, Dennis Saadeh, and Andrew R. Boll**, further agree that upon request we will provide promptly all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible and will testify as to the same in any interference, litigation or proceeding related thereto and will promptly execute and deliver to **Imprimis Pharmaceuticals, Inc.** or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application(s), said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof.

All of the above shall be held and enjoyed by said **Imprimis Pharmaceuticals, Inc.** for its own use and benefit, and for its successors, legal representatives and assigns, to the full end of the term for which said Letters Patent may be granted, and we hereby authorize and request the Commissioner of Patents and Trademarks to issue the said Letters Patent in accordance with this Assignment.

12 July 2017
Date


Matthew J. Buderer

Date

Dennis Saadeh

Date

Andrew R. Boll

Attorney Docket No.: 591897: IPI-002CIP

All of the above shall be held and enjoyed by said **Imprimis Pharmaceuticals, Inc.** for its own use and benefit, and for its successors, legal representatives and assigns, to the full end of the term for which said Letters Patent may be granted, and we hereby authorize and request the Commissioner of Patents and Trademarks to issue the said Letters Patent in accordance with this Assignment.

Date

Matthew J. Buderer

7-3-17
Date



Dennis Saadeh

Date

Andrew R. Boll

All of the above shall be held and enjoyed by said **Imprimis Pharmaceuticals, Inc.** for its own use and benefit, and for its successors, legal representatives and assigns, to the full end of the term for which said Letters Patent may be granted, and we hereby authorize and request the Commissioner of Patents and Trademarks to issue the said Letters Patent in accordance with this Assignment.

Date

Matthew J. Buderer

Date

Dennis Saadeh

6/29/2017
Date

Andrew R. Boll
Andrew R. Boll